Mark Varney

Mark Varney

Psychogenics
Verified email at psychogenics.com
Cited by 6751
CNS Drug Discovery
Longbin Liu

Longbin Liu

CHDI Foundation
Verified email at chdifoundation.org
Cited by 6055
CNS drug discovery protein degradation targeting RNA
John A Allen

John A Allen

Associate Professor, Department of Pharmacology, University of Texas Medical Branch
Verified email at utmb.edu
Cited by 5717
GPCRs Neuropharmacology CNS Drug Discovery Chemical Neuroscience Dopamine receptors
David E. Olson

David E. Olson

Professor of Chemistry and of Biochemistry & Molecular Medicine, University of California
Verified email at ucdavis.edu
Cited by 4926
Synthetic Organic Chemistry Chemical Neuroscience Neuropharmacology CNS Drug Discovery
István Gyertyán

István Gyertyán

group leader, MTA-SE NAP B Cognitive Translational Behavioural Pharmacology Group …
Verified email at med.semmelweis-univ.hu
Cited by 3667
behavioural pharmacology CNS drug discovery
Dario Doller

Dario Doller

Alcyoneus ScienceWorks, LLC
Cited by 3619
CNS drug discovery
Stephanie M McTighe

Stephanie M McTighe

Associate Director, Arkuda Therapeutics
Verified email at arkudatx.com
Cited by 882
CNS drug discovery Pharmacology Neurodegeneration Neurodevelopmental disorders Animal models
Vien Nguyen

Vien Nguyen

UNT Health Science Center
Verified email at unthsc.edu
Cited by 788
Neuroscience CNS drug discovery Analytical chemistry Mass spectrometry Pharmacokinetics
Isaac Schiefer

Isaac Schiefer

University of Toledo
Verified email at utoledo.edu
Cited by 744
CNS Drug Discovery
Zsolt Szeleczky

Zsolt Szeleczky

Richter Gedeon Plc.
Verified email at richter.hu
Cited by 132
Medicinal chemistry CNS Drug Discovery Chiral separation
1 - 10